Dataset: Health Canada Accelerated Review Pathways

About this Dataset

Health Canada Accelerated Review Pathways

A Cohort Study of Therapeutic Innovation

About this dataset

This dataset examines the use of accelerated approval pathways by Health Canada between 1995 and 2016 and how it impacts therapeutic gain from new products. It includes data from the Therapeutic Products Directorate, Biologics and Genetic Therapies Directorate, Notice of Compliance database, Notice of Compliance with conditions website, Patented Medicine Prices Review Board La revue Prescrire, and World Health Organization's Anatomical Therapeutic Chemical (ATC) classification system. Supplementary Table 1 contains information on all drugs that received therapeutic assessement while Supplementary Table 2 concentrates on those without such assessments. Developing an understanding of these pathways is able to provide insight into our current healthcare system as well as potential innovative treatments for diseases in which traditional medications have failed or are potentially too costly. Dive deep into this dataset to uncover new breakthroughs in treatments!

More Datasets

For more datasets, click here.

Featured Notebooks

🚨 Your notebook can be here! 🚨!

How to use the dataset

This dataset provides insights into the use of accelerated review pathways by Health Canada from 1995 to 2016, and the relationship between these pathways and the therapeutic benefits of drugs in that time period. In order to use this dataset effectively, it is important to understand what each column represents.

The first two columns of Supplementary Table 1 contain information about a drug’s brand name (Brand Name) and generic name (Generic Name). The third column identifies whether or not a therapeutic benefit was assessed at review (Therapeutic Benefit Assessed?). If yes, further information is provided with regards to the type of benefit assessment conducted (Therapeutic Benefit Triggers and Explanation). The fourth column contains information on which accelerated approval pathway was used for each drug if applicable (Accelerated Review Pathway). Additional columns are included for reference such as ATC Code which indicates the drug’s WHO classification, Review Priority Level which identifies if any priority programs were in place during assessment, Number Approved Submissions which indicates how many new drugs were approved during one year period, Targeted Activities and Regulations which indicate any specific targets set regarding a particular submission process or regulation while reviewing a product.

All other optional columns in Supplementary Table 1 consist of additional details regarding drugs efficacy data sources utilized during their review such as Patented Medicine Prices Review Board(PMPRB),La Revue Prescrire(LP) etc..

Supplementary Table 2 contains 4 columns - Brand Name(drug manufacturer's brand name for product), Generic_Name(active ingredient responsible for pharmacological action when given at therapeutic doses),Number_of_Products_Approved(number of submissions approved by regulator against total number applied)and ATCCode(ATC codes describe active substance content including age indication & related therapeutics effects).

Overall this dataset covers a wide range of data points that can be used effectively to explore the relationship between Health Canada’s use of accelerated review pathways from 1995-2016 and the therapeutic gain offered by new products

Research Ideas

Assessing the effects of using accelerated pathways on therapeutic outcomes by comparing drugs approved through an accelerated pathway versus those approved through traditional pathways.

Investigating how accelerated approval pathways effect drug prices and cost effectiveness.

Examining the link between Health Canada’s use of accelerated review paths and the patient population that can benefit from newly listed drugs

Acknowledgements

If you use this dataset in your research, please credit the original authors.
Data Source

License

License: CC0 1.0 Universal (CC0 1.0) - Public Domain Dedication
No Copyright - You can copy, modify, distribute and perform the work, even for commercial purposes, all without asking permission. See Other Information.

Columns

File: Supplementary Table 1.csv

File: Supplementary Table 2.csv

Acknowledgements

If you use this dataset in your research, please credit the original authors.
If you use this dataset in your research, please credit .

Tables

Supplementary Table 1

@kaggle.thedevastator_health_canada_accelerated_review_pathways.supplementary_table_1

26.33 KB
514 rows
11 columns


CREATE TABLE supplementary_table_1 (
  "supplementary_1_all_drugs_approved_between_1995_2016_t_5327c37c" VARCHAR,
  "unnamed_1" VARCHAR,
  "unnamed_2" VARCHAR,
  "unnamed_3" VARCHAR,
  "unnamed_4" VARCHAR,
  "unnamed_5" VARCHAR,
  "unnamed_6" VARCHAR,
  "unnamed_7" VARCHAR,
  "unnamed_8" VARCHAR,
  "unnamed_9" VARCHAR,
  "unnamed_10" VARCHAR
);

Supplementary Table 2

@kaggle.thedevastator_health_canada_accelerated_review_pathways.supplementary_table_2

12.6 KB
116 rows
10 columns


CREATE TABLE supplementary_table_2 (
  "supplementary_2_all_drugs_approved_between_1995_2016_t_bff1c6f7" VARCHAR,
  "unnamed_1" VARCHAR,
  "unnamed_2" VARCHAR,
  "unnamed_3" VARCHAR,
  "unnamed_4" VARCHAR,
  "unnamed_5" VARCHAR,
  "unnamed_6" VARCHAR,
  "unnamed_7" VARCHAR,
  "unnamed_8" VARCHAR,
  "unnamed_9" VARCHAR
);